{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23"}]}],"title":"BM and/or blood relapse"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"Extramedullary only"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"}]}],"title":"Unknown"}],"denoms":[{"counts":[{"groupId":"OG000","value":"71"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Anatomical location of relapse in participants who achieved prior CR/CRi subsequent to tisagenlecleucel infusion.","groups":[{"description":"Pediatric patients with relapsed or refractory B-cell ALL who were treated with single dose of tisagenlecleucel (CTL019).","id":"OG000","title":"Main Cohort: Single Dose of CTL019"},{"description":"Pediatric B-ALL patients who are very high risk at first relapse.","id":"OG001","title":"Cohort 1: Single Dose of CTL019"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"FAS: The Full analysis set comprised all patients who received infusion of tisagenlecleucel and who achieved CR or CRi. Achieving CR or CRi\" requireb confirmation but for this analysis, all patients with one CR/CRi, regardless of confirmation were included.","reportingStatus":"POSTED","timeFrame":"60 months","title":"Site of Involvement of Subsequent Relapse","type":"SECONDARY","unitOfMeasure":"Participants"}